P eople with limited-stage small cell lung cancer may benefit from adding immunotherapy to chemoradiation, but not if both ...

Summary and Introduction Clinical Application—Disease Entities Theoretical Framework for Therapy−The 'Steel Paradigm' Conclusion References Theoretical Framework for Therapy−The 'Steel ...

Atezolizumab did not improve overall survival, progression-free survival, distant metastasis-free survival, or time to local failure.

Chemoradiation (CRT), a combination of chemotherapy and radiotherapy, has been the standard treatment for cervical cancer ...

NKTR-255 in combination with durvalumab following chemoradiation was well-tolerated in patients with non–small cell lung ...

1 These data support the conclusion that patients who respond to preoperative chemoradiation therapy, who in this study were represented to a greater degree in the LAR group than in the APR group ...

Therapeutics and collaborators at The University of Texas MD Anderson Cancer Center presented late-breaking results from a Phase ...

Updated findings from the phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study (NCT04221945) show the survival advantages of ...

The top stories in non-small cell lung cancer (NSCLC) for 2024 included practice-changing results in EGFR-mutant disease, an ...

Johnson & Johnson Announced one of two Phase 3 clinical trials in difficult to treat muscle-invasive bladder cancer (MIBC) that included treatment with cetrelimab was being discontinued for not ...

Third, chemotherapy given as part of concurrent chemoradiation may act systemically and potentially eradicate distant micrometastases.